Nika Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NIKA research report →
Companywww.nikapharmaceuticals.com
Nika Pharmaceuticals, Inc. , a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV.
- CEO
- Dimitar Slavchev Savov
- IPO
- 2024
- HQ
- Henderson, NV, US
Price Chart
Valuation
- Market Cap
- $534.76M
- P/E
- -6961.93
- P/S
- 0.00
- P/B
- -1719.56
- EV/EBITDA
- -6961.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 27.39%
- ROIC
- 24.70%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-76,398 · 20.25%
- EPS
- $-0.00 · 0.00%
- Op Income
- $-76,398
- FCF YoY
- 42.73%
Performance & Tape
- 52W High
- $0.96
- 52W Low
- $0.20
- 50D MA
- $0.58
- 200D MA
- $0.51
- Beta
- 0.07
- Avg Volume
- 218
Get TickerSpark's AI analysis on NIKA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NIKA Coverage
We haven't published any research on NIKA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NIKA Report →